News & Events : Press Releases
October 28, 2014
FORMA THERAPEUTICS APPOINTS HELEN BOUDREAU, CHIEF FINANCIAL OFFICER, TO EXECUTIVE LEADERSHIP TEAM
WATERTOWN, Mass. – October 28, 2014 – FORMA Therapeutics announced today that Helen M. Boudreau has been appointed to the position of Chief Financial Officer. Helen joins FORMA with over 25 years' global experience in finance, strategy and operations within the pharmaceutical, commercial banking and consumer sectors.
For the past six years, Helen has served at Novartis, most recently as Chief Financial Officer, Novartis Corporation, where she was responsible for treasury, tax, insurance, investor relations, the Finance Shared Service Center and financial management for corporate entities within the United States. Previously, Helen served as Vice President, Investor Relations and was the Global Chief Financial Officer for Novartis Oncology. Prior to joining Novartis, Helen held various leadership positions for 10 years at Pfizer, where she last served as Vice President, Finance for the Customer Business Unit and Commercial Operations. Previously at Pfizer, Helen spent eight years in R&D in roles of increasing responsibility for Global R&D Finance, Research Finance and Procurement, Financial Planning & Strategic Analysis, and Strategic Management.
“Helen’s broad expertise in driving efficiency and productivity improvements for new product development is an extraordinary fit for FORMA as we advance our wholly owned portfolio into IND-enabling studies. Her organizational leadership and mastery of profitability analysis, R&D strategy and integrating mergers and acquisitions is ideally suited for impact within FORMA’s capital efficient and partnership-centric structure,” said Steven Tregay, Ph.D., President and CEO, FORMA Therapeutics. “Helen shares a common purpose with our passionate team, who are working relentlessly to discover ground-breaking medicines. Our team has a tremendous commitment and drive for the success of our programs, and we are embracing the concept that all our employees are ‘sequential founders’ of FORMA Therapeutics.”
“FORMA’s novel R&D platform, exploring entire target families coupled within a unique network of academic partnerships and virtual ADDCOs to interrogate clinical hypotheses, represents an exciting framework for strategic financial planning and portfolio analysis,” said Helen Boudreau. “I am very excited to join such an entrepreneurial company with a strong balance sheet, innovative R&D team and unlimited possibilities to impact human health.”
Before joining the pharmaceutical sector, Helen gained expertise in strategic planning in the restaurant division of PepsiCo/YUM Brands, was an Engagement Manager at McKinsey & Co and was a Commercial Banking Officer at Bank of America. Helen received a B.A. in economics, summa cum laude, from the University of Maryland and an MBA with honors from the Darden School of Business at the University of Virginia, where she is a member of the Corporate Advisory Board.
About FORMA Therapeutics
FORMA Therapeutics' scientists are passionate about discovering and developing medicines that will make a difference in oncology and other genetically driven therapeutic areas. The company's drug discovery engine drives screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis and protein-protein interactions. Deep biological insight across targets is combined with the company's chemistry expertise and integrated with a world class network of academic investigators, clinical experts and corporate partners to rapidly direct the creation of high quality, innovative drug candidates.
FORMA is headquartered in Watertown, MA near the epicenter of the Cambridge Life Sciences cluster, with additional chemistry operations in Branford, CT.